Page 35 - FLIPBOOK
P. 35
Cardiovascular risk profiles of GnRH agonists and antagonists:
real-world analysis from UK general practice
▪ In an analysis of a UK primary care database of N=9,081 patients aged ≥401:
▪ Significantly fewer patients on antagonists had a CV event, compared with patients on LHRH
agonists (6.9% vs 17.7%, p=0.01)*
CV: cardiovascular; LHRH, luteinising hormone-releasing hormone.; *More patients on atagonists had pre-existing CVD at
baseline compared with patients on agonists. 1.) Davey P and Kirby M. J Urol. 2020;203(4S):e250–e251.